Virtu Financial LLC Sells 1,561 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Virtu Financial LLC lessened its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 18.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,881 shares of the company’s stock after selling 1,561 shares during the period. Virtu Financial LLC’s holdings in Mirum Pharmaceuticals were worth $203,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of MIRM. Octagon Capital Advisors LP acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $738,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Mirum Pharmaceuticals by 0.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 6,495,392 shares of the company’s stock worth $191,744,000 after buying an additional 25,000 shares in the last quarter. Boone Capital Management LLC grew its position in shares of Mirum Pharmaceuticals by 25.7% during the 4th quarter. Boone Capital Management LLC now owns 490,139 shares of the company’s stock worth $14,469,000 after buying an additional 100,348 shares during the period. Cadian Capital Management LP increased its stake in shares of Mirum Pharmaceuticals by 34.8% in the 4th quarter. Cadian Capital Management LP now owns 1,934,922 shares of the company’s stock valued at $57,119,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Partners Group Holding AG acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $539,000.

Mirum Pharmaceuticals Trading Up 2.9 %

NASDAQ MIRM opened at $32.05 on Monday. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. The business has a fifty day simple moving average of $25.64 and a 200 day simple moving average of $27.20. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $35.56. The firm has a market capitalization of $1.51 billion, a P/E ratio of -8.64 and a beta of 1.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. The firm had revenue of $69.22 million during the quarter, compared to analysts’ expectations of $69.71 million. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.42 EPS for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total value of $128,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Eric Bjerkholt bought 2,000 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, March 27th. The stock was purchased at an average cost of $24.80 per share, with a total value of $49,600.00. Following the transaction, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The disclosure for this sale can be found here. 22.87% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. SVB Leerink decreased their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Citigroup increased their price target on Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. Baird R W upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Finally, Morgan Stanley increased their target price on Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $53.64.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.